|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NRXN2 |
Gene summary for NRXN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NRXN2 | Gene ID | 9379 |
| Gene name | neurexin 2 | |
| Gene Alias | NRXN2 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q9P2S2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9379 | NRXN2 | HCC1 | Human | Liver | HCC | 2.53e-11 | 2.75e+00 | 0.5336 |
| 9379 | NRXN2 | S014 | Human | Liver | HCC | 1.40e-09 | 2.95e-01 | 0.2254 |
| 9379 | NRXN2 | S015 | Human | Liver | HCC | 1.42e-09 | 4.76e-01 | 0.2375 |
| 9379 | NRXN2 | S016 | Human | Liver | HCC | 9.35e-20 | 6.04e-01 | 0.2243 |
| 9379 | NRXN2 | S027 | Human | Liver | HCC | 3.40e-03 | 2.13e-01 | 0.2446 |
| 9379 | NRXN2 | S028 | Human | Liver | HCC | 2.76e-10 | 3.45e-01 | 0.2503 |
| 9379 | NRXN2 | S029 | Human | Liver | HCC | 2.15e-13 | 3.66e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004409111 | Liver | HCC | membrane biogenesis | 37/7958 | 55/18723 | 1.79e-04 | 1.41e-03 | 37 |
| GO:007170911 | Liver | HCC | membrane assembly | 34/7958 | 50/18723 | 2.38e-04 | 1.79e-03 | 34 |
| GO:00096124 | Liver | HCC | response to mechanical stimulus | 113/7958 | 216/18723 | 2.20e-03 | 1.10e-02 | 113 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| NRXN2 | NLGN1 | NRXN2_NLGN1 | NRXN | Endometrium | ADJ |
| NRXN2 | NLGN1 | NRXN2_NLGN1 | NRXN | Esophagus | ESCC |
| NRXN2 | NLGN2 | NRXN2_NLGN2 | NRXN | Esophagus | ESCC |
| NRXN2 | NLGN3 | NRXN2_NLGN3 | NRXN | Esophagus | ESCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NRXN2 | SNV | Missense_Mutation | rs776114680 | c.5078N>T | p.Pro1693Leu | p.P1693L | Q9P2S2 | protein_coding | tolerated(0.08) | benign(0.174) | TCGA-A2-A0T3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NRXN2 | SNV | Missense_Mutation | novel | c.3029C>A | p.Pro1010Gln | p.P1010Q | Q9P2S2 | protein_coding | tolerated(0.22) | possibly_damaging(0.565) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| NRXN2 | SNV | Missense_Mutation | c.3061C>G | p.Arg1021Gly | p.R1021G | Q9P2S2 | protein_coding | tolerated(0.06) | possibly_damaging(0.635) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| NRXN2 | SNV | Missense_Mutation | c.2816C>G | p.Ser939Cys | p.S939C | Q9P2S2 | protein_coding | deleterious(0) | possibly_damaging(0.806) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NRXN2 | SNV | Missense_Mutation | rs780815530 | c.775N>A | p.Glu259Lys | p.E259K | Q9P2S2 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NRXN2 | SNV | Missense_Mutation | rs772463642 | c.3908N>A | p.Gly1303Asp | p.G1303D | Q9P2S2 | protein_coding | tolerated(0.14) | possibly_damaging(0.752) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| NRXN2 | SNV | Missense_Mutation | c.2333C>T | p.Ala778Val | p.A778V | Q9P2S2 | protein_coding | deleterious(0.03) | possibly_damaging(0.688) | TCGA-B6-A0WX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| NRXN2 | SNV | Missense_Mutation | rs754853667 | c.2404G>A | p.Gly802Ser | p.G802S | Q9P2S2 | protein_coding | tolerated(0.06) | possibly_damaging(0.455) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| NRXN2 | SNV | Missense_Mutation | c.3995N>A | p.Arg1332Gln | p.R1332Q | Q9P2S2 | protein_coding | tolerated(0.51) | benign(0.013) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NRXN2 | SNV | Missense_Mutation | c.1311N>A | p.Asp437Glu | p.D437E | Q9P2S2 | protein_coding | deleterious(0.01) | possibly_damaging(0.777) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |